Jane Barratt | Global Advisor and Former Secretary General
International Federation on Ageing

Jane Barratt, Global Advisor and Former Secretary General, International Federation on Ageing

Dr. Jane M Barratt, is an internationally recognized advisor and non-executive leader with extensive experience in global ageing, health, and social policy.  She serves on multiple international boards and committees, bringing expertise in governance, strategic planning, and interdisciplinary collaboration.  Jane is data-driven, with a strong track record in performance assessment, risk evaluation, and stakeholder engagement.  She is a persuasive communicator known for integrity, transparency, and building consensus across sectors.  Over a 30-year career, Jane has influenced policy and led systemic change in collaboration with agencies such as the World Health Organization (WHO), United Nations (UN), and various governments, academia and civil society.  Her work focuses on advancing public health agendas, improving the resilience of health systems, and population health.  Jane is respected for her judgment, accountability, and commitment to inclusivity and equity.  Her dedication to enhancing the quality of life for older adults has earned her international recognition and trust.  She is diligent, results-oriented, and passionate about promoting lifelong well-being and dignity in ageing. Among her many current positions Jane is a Member, Equitable immunization as part of primary health care across the life course working group, WHO Immunisation Agenda 2030 (IA2030), WHO Global Network on Long Term Care, WHO Clinical Consortium on Healthy Ageing, World Federation Public Health Association Immunisation Task Force, European Interdisciplinary Council on Ageing Scientific Board, International Association Geriatrics and Gerontology (IAGG) e-TRIGGER Board, Vision Academy, Baycrest Seniors Care Board, Baycrest Geriatric Centre Board and Vice Chair Baycrest Academy Research and Education Board. 

Appearances:



Day 3 - Thursday 16th October @ 10:30

Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era

  • Systemic investment barriers to vaccine investment; high R&D costs, uncertain returns, market distortions, and socio-political linked demand uncertainty impact vaccine investment
  • The impacts of fiscal austerity, the rise of transactional aid, and shifting priorities on transitional funding methods, partnerships and equitable access
  • How to incentivise R&D in this evolving landscape to prevent innovation stalling and accelerate breakthroughs
  • Exploring sustainable, scalable solutions to fill the gap left by declining public-sector funding; blended finance, pooled procurement, and value-based pricing
  • Real world case studies: GAVI’s AMC, CEPI’s equity clauses, pharma-NGO coalitions

Day 3 - Thursday 16th October @ 12:45

Combination Vaccines as Equity Accelerators: Can Co-Administration Ease the Burden on Health Systems?

  • Exploring the scientific, clinical, and operational benefits of vaccine co-formulation for equity, efficacy, and broader protection – what diseases cluster geographically (e.g., schiso & dengue?)
  • Challenges in developing compatible combination vaccines; ensuring immunogenic compatibility
  • Case study: Measles/MPOX in Gaza, heat-stable malaria/hookworm combos, mRNA vaccine co-administration and implications for future NTD combinations
  • Health system resilience, reducing immunisation burdens to enhance vaccine access in resource-limited settings
  • Economic insights and equity considerations from LMIC perspective – how can combination vaccines cut delivery costs by 30-40%?

Day 3 - Thursday 16th October @ 15:00

Life-Course Immunisation: Are Combination Vaccines the Only Viable Path Forward for Adults?

  • Evaluating the economic and societal case for routine adult and life-course immunisation,
  • What next-generation combination vaccines are approaching approval, and when will health systems realistically adopt them?
  • Will standalone new vaccines remain viable, or is the future exclusively in combination vaccines?
  • Strategies for integrating novel antigens into existing vaccine presentations and delivery systems
  • Policy, procurement, and health system strategies to sustainably deliver true life-course immunisation.
last published: 07/May/25 13:55 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2025

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com

 

Otto Squire
Otto.Squire@terrapinn.com

 

TO SPEAK


Anna Hindley-Skelt
Anna.Hindley-Skelt@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.